Inhibitors directed against the molecules CDK4/6, which are essential for the initiation and development of breast cancer and ALL, demonstrated growth inhibition in various cancers as well as induction of anti-tumor immunity by enhancing TAA expression and inhibiting regulatory T cell proliferation (81, 82). Here, CDK4 is linked to neoplasm.